Humacyte Inc (HUMA)

$1.00 -0.02 (-2.06%)
Market Cap 186.84M
Revenue (ttm) 0.00
Net Income (ttm) -148.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,934,700
Avg Vol 4,703,576
Day's Range N/A - N/A
Shares Out 187.27M
Stochastic %K 24%
Beta 1.93
Analysts Strong Sell
Price Target $7.71

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 313 9633
Address:
2525 East North Carolina Highway 54, Durham, United States
David_M_
David_M_ Feb. 4 at 1:11 AM
$HUMA
0 · Reply
goodguyvs
goodguyvs Feb. 4 at 12:39 AM
$HUMA jumped up the short squeeze score chart things are cooking. Question is do they flush it before the run?
0 · Reply
Diefreeandsell
Diefreeandsell Feb. 3 at 9:02 PM
$HUMA The $1 battle rages on!
1 · Reply
Pitchie
Pitchie Feb. 3 at 6:15 PM
$HUMA https://www.facebook.com/share/1CGzKRNZec/
0 · Reply
Outperformer
Outperformer Feb. 3 at 5:24 PM
$HUMA anyone have real/good info on this? Im down heavily as this is a hail mary play for me, Im willing to double down and average down on my position, anyone want to persuade or dissuade me?
4 · Reply
Skyrocket101
Skyrocket101 Feb. 3 at 2:37 PM
$HUMA Lets ROCKET SHORT SQUEEZE THIS!!! ABOUT 25% SHORTED AND INTEREST RATE TO BORROW IS INCREASING!!! BUY BUY BUY!!!
0 · Reply
Merdyflirty123
Merdyflirty123 Feb. 3 at 12:22 PM
$HUMA When are we going to the moon???
0 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Feb. 2 at 10:35 PM
$HUMA @MarketPro Hey Brad - Did anything ever come of this?
3 · Reply
Runmaster83
Runmaster83 Feb. 2 at 9:09 PM
$HUMA Closed at HOD!
1 · Reply
Diefreeandsell
Diefreeandsell Feb. 2 at 6:10 PM
$HUMA the $1 battle rages on!
1 · Reply
Latest News on HUMA
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Jan 8, 2026, 8:00 AM EST - 26 days ago

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Jan 5, 2026, 8:00 AM EST - 4 weeks ago

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Dec 22, 2025, 8:00 AM EST - 6 weeks ago

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Dec 16, 2025, 8:00 AM EST - 7 weeks ago

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Nov 20, 2025, 8:00 AM EST - 2 months ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Nov 13, 2025, 8:00 AM EST - 2 months ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:21 PM EST - 2 months ago

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:00 AM EST - 2 months ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Nov 10, 2025, 8:00 AM EST - 3 months ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Nov 6, 2025, 8:00 AM EST - 3 months ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Oct 7, 2025, 9:00 AM EDT - 4 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Oct 6, 2025, 8:00 AM EDT - 4 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Sep 29, 2025, 8:00 AM EDT - 4 months ago

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Sep 18, 2025, 7:00 AM EDT - 4 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Sep 15, 2025, 7:00 AM EDT - 5 months ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Aug 12, 2025, 1:20 PM EDT - 6 months ago

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 10:00 AM EDT - 6 months ago

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 7:00 AM EDT - 6 months ago

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Jul 23, 2025, 8:00 AM EDT - 6 months ago

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Jul 8, 2025, 8:00 AM EDT - 7 months ago

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Humacyte: Revenue Ramp From Symvess Incoming

Jun 11, 2025, 9:05 AM EDT - 8 months ago

Humacyte: Revenue Ramp From Symvess Incoming

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Jun 9, 2025, 8:00 AM EDT - 8 months ago

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Jun 2, 2025, 8:00 AM EDT - 8 months ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

May 19, 2025, 4:05 PM EDT - 9 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:29 PM EDT - 9 months ago

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 9 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

May 9, 2025, 8:00 AM EDT - 9 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Mar 28, 2025, 1:48 PM EDT - 11 months ago

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 28, 2025, 7:30 AM EDT - 11 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Mar 26, 2025, 8:00 AM EDT - 11 months ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Mar 25, 2025, 8:35 PM EDT - 11 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Mar 25, 2025, 4:01 PM EDT - 11 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 10, 2025, 8:00 AM EDT - 11 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Trestle Bio Announces Research Collaboration with Humacyte

Mar 6, 2025, 8:00 AM EST - 11 months ago

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 1 year ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Feb 27, 2025, 8:00 AM EST - 1 year ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Feb 26, 2025, 8:00 AM EST - 1 year ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Feb 20, 2025, 1:35 PM EST - 1 year ago

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Jan 21, 2025, 8:00 AM EST - 1 year ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Jan 17, 2025, 10:30 AM EST - 1 year ago

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

David_M_
David_M_ Feb. 4 at 1:11 AM
$HUMA
0 · Reply
goodguyvs
goodguyvs Feb. 4 at 12:39 AM
$HUMA jumped up the short squeeze score chart things are cooking. Question is do they flush it before the run?
0 · Reply
Diefreeandsell
Diefreeandsell Feb. 3 at 9:02 PM
$HUMA The $1 battle rages on!
1 · Reply
Pitchie
Pitchie Feb. 3 at 6:15 PM
$HUMA https://www.facebook.com/share/1CGzKRNZec/
0 · Reply
Outperformer
Outperformer Feb. 3 at 5:24 PM
$HUMA anyone have real/good info on this? Im down heavily as this is a hail mary play for me, Im willing to double down and average down on my position, anyone want to persuade or dissuade me?
4 · Reply
Skyrocket101
Skyrocket101 Feb. 3 at 2:37 PM
$HUMA Lets ROCKET SHORT SQUEEZE THIS!!! ABOUT 25% SHORTED AND INTEREST RATE TO BORROW IS INCREASING!!! BUY BUY BUY!!!
0 · Reply
Merdyflirty123
Merdyflirty123 Feb. 3 at 12:22 PM
$HUMA When are we going to the moon???
0 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Feb. 2 at 10:35 PM
$HUMA @MarketPro Hey Brad - Did anything ever come of this?
3 · Reply
Runmaster83
Runmaster83 Feb. 2 at 9:09 PM
$HUMA Closed at HOD!
1 · Reply
Diefreeandsell
Diefreeandsell Feb. 2 at 6:10 PM
$HUMA the $1 battle rages on!
1 · Reply
fatpie68
fatpie68 Feb. 2 at 4:23 PM
Yeah, that was a qtrly report according to ThinkOrSwim but perhaps they have it wrong. AI also says 3/27 though. I sent an email to $HUMA weeks ago but haven't heard back.
0 · Reply
APman
APman Feb. 2 at 3:45 PM
$HUMA Out of powder!
1 · Reply
Jptrader3
Jptrader3 Feb. 2 at 2:45 PM
$HUMA Bought more.
0 · Reply
Rybod30
Rybod30 Feb. 2 at 2:45 PM
$HUMA Pierced $.97, oh boy….
0 · Reply
fatpie68
fatpie68 Feb. 2 at 12:45 PM
$HUMA gave it's Q4 2024 report on 3/28/25, so I'm not surprised with the Q4 2025 report coming out on 3/27/25.
2 · Reply
BZT777
BZT777 Feb. 2 at 12:39 PM
$HUMA Hmmm... I'm wondering if something good is brewing here. Their normal ER cadence is week 2 of the 2nd month but they pushed it out to the end of the 3rd month. - Buyout? -Finalizing DOD order? -Anticipating early approval in Israel? I'll take any one or combination of....
0 · Reply
cdaviscamera
cdaviscamera Feb. 2 at 1:06 AM
$HUMA Waiting patiently for their next earnings report.
0 · Reply
Djpshjt_trader
Djpshjt_trader Feb. 2 at 12:42 AM
$HUMA looks legit...
2 · Reply
SkywalkerAR
SkywalkerAR Feb. 1 at 10:37 PM
$HUMA https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-announces-hospital-charge-data-showing-high-expense/
1 · Reply
Rybod30
Rybod30 Feb. 1 at 6:18 PM
$HUMA Bewildered by the apparent miss with the DOW, I realize there’s more potential for other indications here, but the DOW was my play.🤷‍♂️😬☹️
0 · Reply
SkywalkerAR
SkywalkerAR Feb. 1 at 1:42 PM
$HUMA https://x.com/KNagarshethMD/status/1999875876922839386
0 · Reply
crowbaby333
crowbaby333 Feb. 1 at 2:14 AM
$HUMA
0 · Reply